Moderna Rises as CEO Eyes European Market and Flu-Covid Vaccine
Moderna stock jumps 14%, driven by European expansion plans and a new flu-Covid combo vaccine aiming for 2026 approval.
/ 22 items
#MRNA↓
Wells Fargo Upgrades GLUE, Jefferies Downgrades GBIO
Wells Fargo upgrades Monte Rosa Therapeutics on 2026 catalysts, while Jefferies downgrades Generation Bio due to its pending acquisition by Xoma.
FDA Memo on Vaccine Deaths Sends Moderna, Novavax Stocks Tumbling
Moderna and Novavax shares drop 5-6% after FDA's vaccine chief links COVID-19 shots to 10 children's deaths and announces stricter vaccine approval standards.
Moderna Lowers 2025 Revenue Forecast but Beats Q3 Expectations
Moderna cut its 2025 revenue forecast due to weak U.S. COVID-19 vaccine sales but beat Wall Street’s Q3 estimates, lifting shares premarket.
Moderna Explores Major Deal Options, Including Potential Buyout
Moderna is in discussions with large pharmaceutical companies about significant deals, including a possible buyout.
Moderna Abandons CMV Birth Defect Vaccine After Late-Stage Trial Failure
Moderna discontinues its cytomegalovirus vaccine development after Phase 3 trial shows only 6-23% efficacy, missing targets for preventing congenital birth defects in a major setback for the biotech company.